A.P. Pharma Names New Vice President of Clinical Development
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 20, 2006--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today announced that Anastassios D. Retzios, Ph.D. has joined the Company in the newly created position of Vice President of Clinical Development, reporting to Gregory Turnbull, the Company's Chief Executive Officer. Dr. Retzios has more than 18 years of experience in a wide range of clinical and regulatory matters, most recently as Director of Global Clinical Research and Development at Baxter BioScience. Previously he served in senior clinical positions at Questcor Pharmaceuticals and Alpha Therapeutic Corporation.
In commenting on the appointment of Dr. Retzios, Mr. Turnbull said "we are delighted to have Anastassios on our team. The experience and expertise he brings to us will be of paramount importance as we pursue our pivotal phase 3 clinical trial for APF530."
APF530 is the Company's lead compound for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial target areas of application for the Company's drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAI applications. For further information visit the Company's web site at www.appharma.com.
CONTACT: A.P. Pharma, Inc.
Stephen C. Whiteford, 650-366-2626
Investor Relations Contacts:
Lippert/Heilshorn & Associates
SOURCE: A.P. Pharma, Inc.